The shift from a longevity niche to a broad preventive health platform positions the business to serve diverse needs—from fertility planning to chronic-disease baselines and school testing—while staying anchored in healthspan objectives.

At-home blood draws are available in 35 states and test kits ship nationwide, with services accessible without insurance or referrals and designed to avoid surprise billing.

The catalog now comprises seven testing categories, including standard panels, at-home kits, imaging and scans, whole-genome sequencing, specialty kits, multi-cancer early detection, and the original biomarker work, plus added imaging like DEXA and whole-body MRI.

The company operates on a flat $9-per-month membership with tests at-cost to minimize incentives for excess testing and to position testing as a core preventive strategy.

This expansion aligns with longevity medicine by providing upstream tools—genetic risk, imaging, and early cancer detection—that enable proactive health management years before problems arise.

Mito Health has surpassed one million lab tests and broadened beyond its initial longevity biomarker panels into a wider preventive-health marketplace.

Overall, the move is framed as building the infrastructure for longevity medicine rather than abandoning longevity, integrating new categories as upstream inputs to track healthspan.

Pricing and business model emphasize transparency and a membership-based approach designed to reduce traditional revenue incentives tied to test volume, contrasting with typical diagnostics industry practices.